Pulmonary arterial hypertension due to the use of amphetamines as drugs or doping;Pulmonale arteriële hypertensie door amfetaminen gebruikt als drugs of doping

Nederlands Tijdschrift voor Geneeskunde

Volumn 149, Issue 23, 2005, Pages 1283-1288

  Van Wolferen, S A ^a   Vonk Noordegraaf, A ^a   Boonstra, A ^a   Postmus, P E ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; AMPHETAMINE DERIVATIVE; METHYLPHENIDATE;

ADULT; ARTICLE; CASE REPORT; CELL PROLIFERATION; DOPING; DRUG DEPENDENCE; DYSPNEA; EXERCISE TOLERANCE; FEMALE; HUMAN; LUNG VASOCONSTRICTION; MALE; PULMONARY HYPERTENSION; RISK FACTOR; SEROTONIN RELEASE; SMOOTH MUSCLE FIBER;

ADULT; AMPHETAMINE-RELATED DISORDERS; AMPHETAMINES; FEMALE; HUMANS; HYPERTENSION, PULMONARY; MALE; MIDDLE AGED;

EID: 20644451639     PISSN: 00282162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Abenhaim L, Moride Y, Brenot F, Rich S, Benichou J, Kurz X, et al. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group. N Engl J Med 1996;335:609-16.
2. Lehtonen J, Sutinen S, Ikaheimo M, Paakko P. Electrocardiographic criteria for the diagnosis of right ventricular hypertrophy verified at autopsy. Chest 1988;93:839-42.
3. Gaine SP, Rubin LJ. Primary pulmonary hypertension. Lancet 1998;352:719-25.
4. Simonneau G, Galie N, Rubin LJ, Langleben D, Seeger W, Domenighetti G, et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol 2004;43:5S-12S.
5. Lane KB, Machado RD, Pauciulo MW, Thomson JR, Phillips 3rd JA, Loyd JF, et al. Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension. The International PPH Consortium. Nat Genet 2000;26:81-4.
6. Mandegar M, Fung YC, Huang W, Remillard CV, Rubin LJ, Yuan JX. Cellular and molecular mechanisms of pulmonary vascular remodelling: role in the development of pulmonary hypertension. Microvasc Res 2004;68:75-103.
7. Rothman RB, Ayestas MA, Dersch CM, Baumann MH. Aminorex, fenfluramine, and chlorphentermine are serotonin transporter substrates. Implications for primary pulmonary hypertension. Circulation 1999;100:869-75.
8. Gainetdinov RR, Wetsel WC, Jones SR, Levin ED, Jaber M, Caron MG. Role of serotonin in the paradoxical calming effect of psychostimulants on hyperactivity. Science 1999;283:397-401.
9. Abramowicz MJ, Haecke P van, Demedts M, Delcroix M. Primary pulmonary hypertension after amfepramone (diethylpropion) with BMPR2 mutation. Eur Respir J 2003;22:560-2.
10. Itkonen J, Schnoll S, Glassroth J. Pulmonary dysfunction in 'freebase' cocaine users. Arch Intern Med 1984;144:2195-7.
11. Schaiberger PH, Kennedy TC, Miller FC, Gal J, Petty TL. Pulmonary hypertension associated with long-term inhalation of 'crank' methamphetamine. Chest 1993;104:614-6.
12. Setola V, Hufeisen SJ, Grande-Allen KJ, Vesely I, Glennon RA, Blough B, et al. 3,4-methylenedioxymethamphetamine (MDMA, 'Ecstasy') induces fenfluramine-like proliferative actions on human cardiac interstitial cells in vitro. Mol Pharmacol 2003;63:1223-9.
13. Roeleveld RJ, Boonstra AB, Voskuyl AE, Bronzwaer JGF, Marques KM, Vonk Noordegraaf A. Diagnostiek van pulmonale hypertensie: ervaringen bij 187 patiënten verwezen naar het VU Medisch Centrum. Ned Tijdschr Geneeskd 2004;148:82-8.